Trials / Completed
CompletedNCT00158873
Pharmaco-Economic Study Of Ultiva In Intensive Care Unit(ICU)Subjects
A Centre-Randomized, Open-Label, Cross-Over Study to Compare the Pharmaco-Economic Consequences of an Ultiva (Remifentanil Hydrochloride) Based Regimen With Conventional Sedative Based Regimens in ICU Subjects Requiring Short-Term Mechanical Ventilation With Analgesia and Sedation
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 224 (planned)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study will evaluate the pharmaco-economic consequences of the use of a remifentanil based regimen compared with a conventional sedative based regimen in terms of duration of mechanical ventilation, length of stay in ICU, difference in extubation time and use of concomitant sedative agents.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | midazolam | |
| DRUG | lorazepam | |
| DRUG | fentanyl | |
| DRUG | morphine | |
| DRUG | remifentanil | |
| DRUG | propofol |
Timeline
- Start date
- 2004-09-01
- First posted
- 2005-09-12
- Last updated
- 2008-10-16
Locations
15 sites across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT00158873. Inclusion in this directory is not an endorsement.